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ABSTRACT 
Primary hepatic leiomyosarcoma are very rare tumours with less than 50 cases reported. Due to nonspecific presentations, 
diagnosis is often delayed until they reach a large size. The rarity of these tumours has precluded our understanding of them 
and therefore the standard of care has not been well defined. We report a 45-year-old lady who presented with loss of appetite, 
abdominal distension and bilateral lower limb swelling and hepatomegaly. CT abdomen revealed nodular hepatomegaly with a 
hypodense lesion on plain scans, heterogenous enhancing lesion on arterial phase and delayed washout on portal venous phase 
occupying segments VII and VIII and involving right hepatic vein and infiltrating into inferior vena cava (IVC). The pathology 
report confirmed the diagnosis of leiomyosarcoma. IHC was positive for SMA, vimentin and weakly positive for desmin stain. 
Due to extensive nature and involvement of IVC, patient was planned for upfront neo-adjuvant chemotherapy (NACT) 
(Ifosfamide, and doxorubicin with MESNA. The patient has completed 6 cycles NACT and had stable disease. The patient was 
then switched to oral Pazopanib and is on follow up.  
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rimary hepatic leiomyosarcoma are rare tumours 
with less than 50 cases reported in the English 
literature. Due to non-specific presentation, 
diagnosis is often delayed until they reach a large 
size with poor response to therapy often leading to a 
dismal prognosis. The rarity of these tumours has 
precluded our understanding of them and therefore, the 
standard of care has not been well defined. We, herein, 
report a case of primary hepatic leiomyosarcoma, which 
was treated with chemotherapy and review the English 
literature with an emphasis on management outcomes. 
CASE REPORT 
A 45-year-old lady was referred to our department with 
loss of appetite for past 9 months, abdominal distension 
and bilateral lower limb swelling for past 6 months. She 
had no history of liver disease or alcohol abuse. Her past 
 
medical history and family history were unremarkable. 
Physical examination revealed a marked hepatomegaly 
extending 13 cm below the right costal margin and 
extending and occupying whole of the epigastrium. The 
hepatomegaly was tender and hard. There was no evidence 
of any other palpable abdominal lump or 
lymphadenopathy. Bilateral pitting pedal edema was also 
present.  
Laboratory analysis revealed normal liver function 
tests including serum albumin level and prothrombin time. 
White blood cell count, platelets, serum α-fetoprotein, CA 
19-9 and carcinoembryonic antigen (CEA) were normal. 
Antibody to hepatitis C virus, human immunodeficiency 
virus (HIV), ebstein barr virus (EBV) and hepatitis B 
surface antigen were negative. Impedance cardiogram 
(ICG) clearance at 15 min was 10%. Abdominal 
P 
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ultrasonography revealed a hypoechoic mass, measuring 
11.9X10.6X9.8 cm, in segment VII and VIII of liver 
without any evidence of intrahepatic biliary radical 
dilatation. Lesion was extending into inferior vena cava 
(IVC) at confluence with significant luminal narrowing.  
Abdominal computed tomography (CT) showed 
nodular hepatomegaly with a hypodense lesion on plain 
scans, heterogeneous enhancing lesion on arterial phase 
and delayed washout on portal venous phase occupying 
segments VII and VIII (Fig. 1) measuring approximately 
115×84×114 mm. It was seen to be involving right hepatic 
vein and infiltrating into IVC causing partial luminal 
compromise. Chest CT, 2D-ECHO and gastrointestinal 
endoscopy were normal. Pretreatment diagnosis was 
unconfirmed; so, biopsy was undertaken after obtaining 
written informed consent. 
The histopathology report confirmed the diagnosis of 
leiomyosarcoma. Light microscopy demonstrated the 
typical pattern of growth of leiomyosarcoma, 
predominantly fascicular, with tumour bundles intersecting 
each other at wide angles and merging of tumour cells with 
blood vessel walls (Fig. 2). The individual cells had 
elongated, blunted nuclei and acidophilic fibrillary 
cytoplasm. Numerous mitoses were present. On 
immunohistochemistry, tumour cells were positive for 
smooth muscle actin (SMA), and vimentin and weakly 
positive for desmin stain (Fig. 3). It was negative for 
pancytokeratin, S-100, HMB-15, CD31, CD117, CD10, 
D2-40 and factor VIII. 
Due to the extensive nature and involvement of IVC, 
patient was planned for upfront neoadjuvant chemotherapy 
(NACT) for 6 cycles (Ifosfamide 1500mg/m
2
 D1-4 + 
Doxorubicin 20mg/m
2
 D1-3 with MESNA 225 mg/m
2
 1 
hour before ifosfamide and at 4 and 8 hrs after ifosfamide). 
After 3 cycles of NACT, MRI abdomen was done which 
revealed a large ill defined soft tissue lesion (approx 10 
x11x11 cm) in right lobe of liver involving segment V, VI, 
VII and VIII displaying heterogenous signal intensity 
alterations (Fig. 4).  
   
Figure1. Arterial (A), venous (B) and delayed portal venous (C) phases on triple phase CECT of liver showing hepatic mass 
involving segment VII and VII compressing and infiltrating into intrahepatic IVC showing well encapsulated heterogenous 
enhancing lesion on arterial phase and delayed washout on venous phase, predominantly supplied by right hepatic artery (1A)
       
Figures: Fig 2 - light microscopy showing fascicular growth pattern with tumor fascicles intersecting each other at wide 
angles and merging of tumor cells with blood vessel. Fig 3 - IHC positive for desmin (A) and SMA (B) 
Fig. 1 A Fig. 1 B Fig. 1 C 
Fig. 2 Fig. 3 A Fig. 3 B 
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Fig 4 A, B, & C - MRI T2 fat suppressed axial views showing a large ill defined soft tissue lesion in right lobe of liver involving 
segment V, VI, VII and VIII displaying heterogenous signal intensity alterations and extending upto the capsule posteriorly 
and laterally. A separate feeder vessel was also noted.  
 
Fig 4 D - MRI T2 coronal view showing a large ill defined 
lesion in right lobe of liver involving segment V, VI, VII & 
VIII displaying heterogenous signal intensity alterations 
and extending up to capsule posteriorly and laterally 
It was extending upto the capsule posteriorly and 
laterally. The lesion was compressing and partially 
extending into intrahepatic portion of IVC. After 
completing 6 cycles of NACT, patient had unresectable 
but stable disease. The patient was then switched to oral 
Pazopanib 800mg OD and is on regular follow up. 
DISCUSSION 
Primary leiomyosarcoma of the liver is a recognized, but 
very rare, malignancy according to the World Health 
Organisation classification [1]. Sarcomas constitute only 
1% to 2% of all primary malignant tumours of the liver 
with majority being either hepatocellular carcinoma or 
cholangiocarcinoma. Nearly all primary sarcomas of liver 
are angiosarcomas, epitheloid hemangioendotheliomas or 
undifferentiated embryonal sarcoma constituting nearly 
70% with leiomyosarcoma constituting only 8-10% of all 
sarcomas. Most hepatic leiomyosarcoma are metastatic 
from other sites including gastrointestinal tract, uterus, 
retroperitoneum and lung. So, exclusion of metastatic 
leiomyosarcoma in liver is an essential event in diagnosing 
a primary lesion.  
Hepatic leiomyosarcoma may arise from intrahepatic 
vascular structures, bile ducts or ligamentum teres. 
Tumours arising from hepatic veins may develop Budd-
Chiari syndrome and have worse prognosis while tumours 
arising from the ligamentum teres have better prognosis 
due to its increased resectability. No underlying etiologic 
factors are known; although, Thorotrast, HIV, EBV, prior 
history of immunosuppression such as post-renal 
transplant and previously treated Hodgkin’s lymphoma 
and cirrhosis due to hepatitis C have been described [2]. 
The median age of diagnosis is 58 years with sporadic 
occurrence of tumor in younger age group and male to 
female ratio is 33 to 34:1 [3]. Primary hepatic 
leiomyosarcoma presents a clinical dilemma as not only 
are they rare, but they are often asymptomatic until they 
become large, when they produce only nonspecific 
symptoms. Patients may be afflicted with a wide spectrum 
of symptoms, such as abdominal pain, weight loss, 
anorexia; vomiting, jaundice and rarely acute intra-
abdominal bleeding secondary to tumor rupture [4]. 
Tenderness of upper abdomen, hepatomegaly, and mass 
may be the main signs. Some patients may have abnormal 
liver function tests but essentially the α-fetoprotein and 
other serological markers are normal. 
Fig. 4 A Fig. 4 B Fig. 4 C 
Fig. 4 D 
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As with other liver tumours, histological pre-operative 
diagnosis of hepatic leiomyosarcoma is controversial as 
most of these tumours are treated presuming to be 
hepatocellular carcinoma with its inherent propensity for 
needle track seeding. Histological examination reveals 
tumor composed of intersecting bundles of spindle-shaped 
cells. Immunohistochemistry is positive for desmin, 
vimentin and SMA but negative for keratin, S-100 protein 
and neuron-specific enolase and FNA biopsy will allow for 
specific FNA diagnosis in most of the cases [5]. 
CT findings of primary hepatic leiomyosarcoma have 
been described as a large, well-defined, heterogeneous 
hypodensity mass with internal and peripheral 
enhancement or cystic mass with an enhancing thick wall. 
Cystic variant of leiomyosarcoma may be misdiagnosed as 
hydatid cyst or liver abscess [6]. On MR imaging, tumor 
displays homogenous or heterogeneous hypointensity on 
Tl-weighted and hyperintensity on T2-weighted images 
with occasional observation of encapsulation [7]. PET-CT 
can be applied to sensitively detect primary tumours and 
metastases.  
Due to the rarity of primary hepatic sarcomas in 
general, and primary hepatic leiomyosarcoma in particular, 
standard of care has not been defined. However, surgical 
resection followed by adjuvant chemotherapy is being 
widely followed in an empirical manner [2]. Hepatic 
leiomyosarcoma has four different histological types. 
Types 1, 2, 3, and 4 are defined as well differentiated, 
moderately differentiated, poorly differentiated, and 
myxoid leiomyosarcoma, respectively. Type 4 or myxoid 
leiomyosarcoma has an aggressive growth pattern. 
Resection surgery forms the cornerstone of successful 
management of primary hepatic leiomyosarcoma with an 
intention of R0 resection. All patients with potentially 
resectable tumours with adequate remnant liver volume 
should undergo surgical exploration and liver resection. 
Criteria for inoperability include extrahepatic spread, 
diffuse intrahepatic tumor making complete tumor removal 
unlikely, and impaired liver function. The role of partial 
resection in multifocal tumours has not been defined. The 
surgical outcome for R0 resection extrapolated from 2 
large series was 67% disease specific survival at 5 years 
with 0% 3 years survival for patients who underwent R1+ 
resection [8]. Age was another major prognostic factor 
with patients less than 50 years achieving better survival. 
Role of adjuvant chemotherapy/chemo radiotherapy is 
not well defined. Adjuvant chemotherapy in the form of 
doxorubicin and ifosfamide seems to slow the course of 
disease and may prolong survival in R1 resections but 
evidence is lacking as data are extrapolated from setting of 
unresectable or metastatic leiomyosarcoma [9]. 
Liver transplant has been attempted sporadically in 
primary hepatic leiomyosarcoma but is not as well defined 
as in primary hepatic epithelioid hemangioendothelioma 
[10]. The outcome for liver transplant has been varied with 
all cases developing recurrent or metastatic disease and 
only one case showing long term survival after undergoing 
resection for local chest wall recurrence [11]. Immune 
status manipulation may play an important role in 
prolonging survival in post transplant period by preventing 
recurrence [3]. 
The efficacy of chemotherapy and radiotherapy for 
leiomyosarcoma is extremely low. Additionally, 
postoperative therapy and management of recurrence are 
not established [12]. Despite being slow growing and 
having late metastasis, leiomyosarcomas carry poor 
prognosis and high incidence of local recurrence. Even 
after complete resection, prognosis is poor and long-term 
observation is required. They tend to metastasize 
hematogenously to the lung, but lymphatic metastasis and 
peritoneal seeding have also been described [13].  
Adjuvant chemoradiotherapy had been recommended 
for eradication of microscopic residual disease. However, 
its success in achieving local control and prolonged patient 
survival needs to be further studied as a meta-analysis has 
shown a small benefit [10]. Postoperative chemo-
radiotherapy has been tried without much success. Chemo-
embolization of metastatic hepatic sarcomas has been 
shown to increase the survival [14]. To have a better 
understanding of these rare tumours, we need to have a 
global database to analyze and understand the outcomes of 
different therapies. 
CONCLUSION 
The rarity of primary hepatic leiomyosarcoma has 
precluded our understanding of them and therefore, the 
standard of care has not been well defined. This case helps 
us to highlight the importance of neoadjuvant 
chemotherapy management of this rare tumor presenting in 
an inoperable situation.  
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